Management of postpneumonectomy empyema and bronchopleural fistula

Ivan Azevedo¹, Ricardo L. Oliveira², Paula A. Ugalde³

¹Division of Thoracic Surgery, Department of Oncology Oncobeda, Doctor Beda General Hospital, Rio de Janeiro, Brazil; ²Division of Thoracic Surgery, Santa Casa de Misericórdia da Bahia, Salvador, Brazil; ³Department of Pulmonology and Thoracic Surgery, Institut Universitaire de Pneumologie et Cardiologie de Quebec, Quebec, QC, Canada

Abstract: Although the number of pneumonectomies performed worldwide is decreasing due to epidemiological changes in lung cancer, increased awareness of postoperative complications of pneumonectomy plays a major role in the proper clinical management and ultimately in the quality of life and survival rate of patients. Postpneumonectomy empyema is a rare but serious complication of pneumonectomy. The prognosis of postpneumonectomy empyema patients mainly depends on when the complication appears and the presence or absence of a bronchopleural fistula (BPF). The majority of empyema will occur within the first 3 months after surgery. The management of postpneumonectomy empyema is a challenge to thoracic surgeons due to the number of surgical approaches available and a lack of consensus as to the best approach. It can vary from a simple rib resection and open drainage to a complete thoracoplasty. Unfortunately, after pneumonectomy, patients who develop BPF and empyema will present prolonged hospitalization and are at risk of high morbidity and mortality rates. Consequently, successful therapy might be difficult to achieve, that is why is so important to well select your strategy. Though this remains an area of controversy in the field of thoracic surgery, accurate and expedited diagnosis is critical to achieve a cure. Regardless of the technique adopted for treatment, adequate pleural drainage, definitive closure of the BPF, sterilization of the pleural cavity, and obliteration of residual space are the key factors to favorable outcomes. In this article, the authors aim to discuss in detail the management strategy based on the clinical evolution of patients with postpneumonectomy empyema and BPF.

Keywords: Pneumonectomy; empyema; bronchopleural fistula

Introduction

Pneumonectomy is the surgical removal of an entire lung and is frequently performed for the management of bronchogenic carcinoma. Pneumonectomy is required when a tumor is located in a central position, such as the main stem bronchus, or when a tumor extends across a major fissure. Rarely, pneumonectomy is performed for the treatment of metastasis; inflammatory lung diseases, such as pulmonary tuberculosis, fungal infections, bronchiectasis; or other benign diseases, such as traumatic lung injury and congenital diseases (1). Despite refinements in both surgical technique and postoperative care of patients who undergo lung cancer resection, pneumonectomy still has very high morbidity and mortality when compared with other types of lung resection (2). Although the number of pneumonectomies performed worldwide is
decreasing due to epidemiological changes in lung cancer, increased awareness of postoperative complications of pneumonectomy plays a major role in appropriate clinical management to achieve good outcomes and ultimately high survival rates.

Empyema after pneumonectomy is an uncommon but serious complication, with a reported incidence of 5% to 10% and mortality of up to 20% (3,4). Most postpneumonectomy empyemas (75%) occur within the first 3 months after surgery (5). Empyema years after the procedure is rare. The prognosis of patients with postpneumonectomy empyema mainly depends on when the complication appears and the presence or absence of a bronchopleural fistula (BPF) (6). Over the years, various strategies have been proposed for the management of postpneumonectomy empyema and BPF, ranging from simple rib resection and open drainage to a complete thoracoplasty. This focused issue of the Shanghai Chest Journal, details “The Role of Pneumonectomy in Thoracic Surgery in The Third Millennium” and in this article, we will discuss the management of postpneumonectomy empyema and BPF.

Clinical features

Empyema thoracis is defined as the collection of pus in the pleural space. It has been recognized since the time of Hippocrates and historically has been associated with high mortality (7). The name comes from Greek word *empyein* meaning pus producing; pus and fluid from infected tissue collects in the body cavity.

The removal of an entire lung is associated with a variety of predictable anatomic changes and a number of potential complications that involve the respiratory system and the pleural space. The absence of the lung in the pleural cavity predisposes to fluid accumulation in this space. This fluid can be colonized by bacteria and cause empyema. This can be aggravated by the presence of bronchopleural fistula, which is the result of bronchial stump dehiscence, thus directly connecting the airways with the pleural cavity. The presence of the fistula offers a greater challenge in treatment and a worse prognosis for these patients. Diabetes mellitus and chronic obstructive pulmonary disease are independent risk factors for postoperative BPF (7,8). Age over 70 years, anemia, poor nutrition, hypoalbuminemia, systemic use of steroids, empyema, neoadjuvant therapy with chemotherapy or radiation, and tracheostomy have also been described as risk factors (9-17). Postoperative mechanical ventilator assistance with positive pressure can affect stump healing and the incidence of dehiscence (11,12,14).

Early postpneumonectomy empyema usually occurs up to 14 days postoperatively and is commonly associated with a bronchial fistula. Late empyema, in which the infection is most often acquired hematogenously, occurs, by definition, more than three months after pneumonectomy. There are reports of empyema diagnosed up to 40 years after the pneumonectomy procedure.

Patients with early infection of the pleural space generally present with one or more of the following symptoms: fever, malaise, thoracic pain, or dyspnea. Occasionally, expectoration of purulent sputum is noted if a BPF is present. In contrast, patients with late empyema show a pattern of chronic infection with nonspecific symptoms such as flu-like symptoms, mild malaise, weight loss, low grade fever, and anorexia. In rare cases, the infection can spread through the chest wall and drain through the overlying skin; this is condition is designated *empyema necessitans*. Almost 50% of cases of both early and late empyema are polymicrobial, and the microorganisms most often found in these infections are *Staphylococcus aureus* and *Pseudomonas aeruginosa* (18).

Management strategy

Diagnosis

Diagnostic investigation begins with a thorough clinical evaluation and imaging tests. Chest x-rays are useful to evaluate contralateral mediastinal deviation, the appearance of air in the pleural collection or a sudden change in an air-fluid level that was previously stable, which suggests a bronchial stump fistula. A contrast chest computed tomography (CT) scan should always be acquired to define the anatomy of the pleural space, the position of diaphragm and the condition of the contralateral lung. A chest CT can also identify peripheral rind enhancement and air-fluid levels and be used to measure the density of the fluid. The chest CT findings may suggest localized or multi-loculated empyema.

Flexible bronchoscopy can confirm or rule-out most BPFs and can be used to establish the precise location and the size of the fistula for therapeutic planning (Figure 1). In patients with microfistulas, the visual component of the exam may be insufficient for diagnosis, and a radiopaque contrast can be used to enhance visualization of the path of the fistula. Lastly, empyema is confirmed by puncture of the postpneumonectomy space for pleural fluid analysis. The
diagnosis is confirmed by the presence of pus, pH <7.25, and positive microbiological results (19).

**Surgical management**

The management of postpneumonectomy empyema remains a challenge to thoracic surgeons due to the number of surgical approaches available and a lack of consensus as to the best approach. Operative management of postpneumonectomy empyema is determined in general by two factors: the timing of the empyema in relation to the surgery and the presence or absence of a BPF. In the acute postoperative stage, the empyema is initially managed with a closed chest tube until the patient is clinically stable and can undergo a surgical procedure. Historically, treatment has ranged from a simple rib resection and open drainage to a complete thoracoplasty depending on the complexity of the case and the extent of the complication. The degree of invasiveness of the technique chosen to approach empyema depends on the chronicity of the empyema, the presence of bronchial fistula as well as the experience of the assistant surgical team. Currently, with the advancement of technology and surgical techniques, minimally invasive approaches using video-assisted thoracic surgery have been shown to be effective in selected cases. The most clinically relevant study of the management of postpneumonectomy empyema was likely a report by Clagett and Geraci (20) in 1963 describing rib resection with open thoracotomy, cavity sterilization after successive debridement, and posterior closure filling the cavity with antibiotic solution after 6 to 8 weeks. Due to technological advances and new diagnostic and treatment tools, we tend to take a less aggressive approach in selected patients in the current era.

The primary cause of empyema has also changed over time. In the past, tuberculous empyema was highly prevalent, and its exclusive treatment was an aggressive approach to the pleural space. With the advent of tuberculostatic medications, this approach to the pleura was reduced to use in patients with complex complications, such as phase 3 empyema. However, bacterial strains are increasingly resistant to antibiotics, which is currently a major cause of pleural complications necessitating a surgical approach to the pleural space.

**Open thoracotomy**

Open window thoracostomy is a definitive and potentially lifesaving procedure for patients with little physiologic reserve and a severely infected pleural space. It consists in an open thoracostomy that has two main goals: allow passive drainage of the infected pleural space by gravity and create a one-way valve that will allow egress of fluid from the chest cavity without the return of air. It was first described by Leo Eloesser (21) in 1935 as a surgical treatment option for patients with tuberculosis and pleural space infections associated with BPFs (22). The technique was later modified by Symbas (23) and coworkers and consists of creating a window in the lower part of the pleural cavity (usually between the 6th and 8th ribs).

Initially, with careful review of the preoperative chest imaging, the steepest zone near the diaphragm is determined to properly place a chest tube sufficient to evacuate the pleural space (Figure 2A). More importantly, this tube may later be used as a physical landmark in the operating room to indicate the optimal location for the open thoracostomy. An inverted U-shaped incision is made at the skin and extended through the soft tissues to the level of the chest wall using electrocautery. After splitting
the muscles of the thoracic wall and the ribs are exposed, segments of two or three adjacent ribs are transected. The U-shaped skin flap is fixed against the diaphragm, creating an epithelialized tract from the postpneumonectomy space to the outside (21,23). A crucial aspect to the creation of an Eloesser flap is selection of an optimal position to allow effective, passive drainage and relatively easy access for open wound packing and patient comfort (Figure 2).

Clagett modified the procedure further by creating a window thoracostomy with open surgery, irrigating with antibiotics, and then closing the window (20). The greatest differences between the Eloesser flap and a Clagett window are that the Clagett window is considerably larger than an Eloesser flap and that the Clagett window was designed to be a temporary strategy to allow decontamination of the pleural space with a subsequent closure (24) after filling the pleural space with antibiotic solution. In contrast, the Eloesser flap is intended to create a permanent drainage window into the pleural space (25). Stafford and Clagett reported a success rate of 75-88% in their series (25). Failure, however, was most often due to recurrent BPF and recontamination of the pleural space (26). To decrease the recurrence rate, Pairolero and associates modified the Clagett procedure by adding one more step to the operation, the transposition of extrathoracic skeletal muscle to reinforce the bronchial stump step before filling the pleural space with antibiotic solution. With this new approach, 84% of their patients had a healed chest wall with no evidence of infection, and 86% of BPFs remained successfully closed (18).

**Muscle flap transposition**

Intrathoracic muscle transposition was described by Abrashoff in 1911 for closure of BPF (27). Since then, muscle flaps have been utilized to obliterate spaces, close BPFs, and reinforce tracheobronchial and esophageal anastomoses. Muscle flaps are considered a good option to fill a contaminated space with or without a BPF because of their excellent blood supply and their ability to reach almost any location in the pleural cavity. The two predominant surgical principles to keep in mind are (I) leave no residual pleural space and (II) ensure that a sufficient number of flaps are available so that any intrathoracic space can be filled. To achieve successful pleural cavity obliteration with muscle flaps, some basic steps should be followed. The patient must be clinically stable with no signs of sepsis, with appropriate antibiotic coverage (based on the sensitivity of the microbiological cultures). They must undergo wide cavity debridement, and in the presence of a BPF, closure should be accomplished. When a BPF is identified, its edges are debrided, and the fistula is closed with an omental flap brought up through an anterior diaphragmatic incision and tacked around the fistula with 3-0 sutures (omentopexy) (27).

Anatomical knowledge of the vascular pedicles of the chest wall musculature is essential to mobilize the flaps used to fill the pleural space. Each muscle has its own particularities and can reach and fill spaces of different sizes. The latissimus dorsi (LD) muscle flap is the largest and is easiest to harvest through a standard incision or a separate small rib resection. Its predominant blood supply is from the thoracodorsal artery. The pedicled LD can be easily applied to apical and mid-intrathoracic spaces. The pectoralis major (PM) is the second largest chest wall muscle. It has a dual blood supply from the predominant thoracodorsal artery to the major pedicle and from the internal mammary artery to the major pedicle and the secondary pedicles. The PM may be used as a reverse turnover flap or be placed directly...
into the wound. It requires a 5-cm rib resection for entry into the chest. A PM flap is the flap of choice for sternal infections but ranks after the LD and serratus anterior for the pleural space and is best suited for apical spaces. The serratus anterior is often a second choice to create a flap for filling a pneumonectomy space, and it is particularly good for filling a small space. The blood supply comes from the lateral thoracic artery, and it can rotate into the chest through the primary incision. Flaps from the rectus abdominis are usually used to repair defects in the lower third of the sternum. Its blood supply comes from the superior epigastric artery (28). Rectus abdominis flaps can also be applied as a filling of the pleural cavity especially in the basal zones but are usually the last choice for this purpose.

In general, an LD flap is used first. If there is failure to achieve full control of the pleural infection, other muscles are used to fill the entire space, depending on anatomical location and size of the space. The pneumonectomy space in a typical adult can usually be filled about 30 to 40% by LD flaps, followed by 20 to 30% by PM flaps and 10 to 15% by omental or rectus abdominis flaps (26,29). Following transposition of the muscle flaps, the wound is closed primarily, and chest tubes are connected to a negative pressure unit for 7 to 10 days while appropriate antibiotics are given.

**Thoracoplasty**

Originally conceived to collapse the cavities of lungs affected by tuberculosis, thoracoplasty reduces the thoracic cavity by removing the ribs. The technique was later extended to the treatment of empyematous cavities. In 1937, Alexander described extrapleural subperiosteal thoracoplasty, the same technique used to this day. Because of the advent of less aggressive procedures, like muscle transposition to fill the pleural space, thoracoplasty was almost completely abandoned (30). However, despite having the bad reputation of being a mutilating operation, studies in the last 25 years have shown that thoracoplasty can be an excellent therapeutic option in selected patients, used alone or in combination with flap transposition to fill the residual space (31,32). Thoracoplasty may be indicated if the post-pneumonectomy space is too large to be filled with muscle flaps. Properly performed, thoracoplasty remains a safe and effective solution for difficult intrathoracic space problems, especially in combination with other filling procedures, provided that the underlying infection is controlled.

Adequate drainage of the space for the control of infection is mandatory for successful thoracoplasty.

The technique for thoracoplasty consists of good exposure of the rib cage with a wide posterolateral incision with scapula elevation to allow the handling of the upper ribs. The rib resection should be done via the subperiosteal and extrapleural plane. Some authors advocate for the removal of the first rib to promote a good collapse of the thoracic apical region, but in some patients, extrapleural detachment (apicollisis described by Semb) (33) from the pleural dome has led to good results with vertical occupation of these cavities. An important step is rib disarticulation at the costovertebral joint, which prevents poor occupation of the posterior gutter. Some authors cite the removal of transverse processes, but this technique is most commonly utilized in patients with severe and symptomatic scoliosis (34).

**Accelerated treatment**

A study from Poland and Switzerland conducted from July 1995 to October 2005 supported the concept of “accelerated” management of early postpneumonectomy empyema without an open window thoracotomy (19). Patients were placed under general anesthesia, and a double-lumen endotracheal tube was placed for ventilation. The technique consisted of radical debridement of the pleural cavity through a thoracotomy and packing the cavity with wet dressings of povidone-iodine. A chest tube under negative pressure was left in place. This procedure was repeated in the operating room every 48 hours, until the chest cavity was “macroscopically clean”. If a BPF was present, the bronchial stump insufficiency was closed and secured by omentopexy. Finally, the pleural space was obliterated with antibiotic solution containing 0.3 g of netilmicin, 2.2 g of ampicillin/clavulanic acid, and 1 g of vancomycin per liter of saline. The median number of interventions until final closure of the chest was 3 (range, 1–8), and the median hospitalization time was 18 days (range, 9–134 days). The patients appreciated having their chests closed generally within a week and being free of a drain or chest wall window. This technique is not considered a good option for patients with chronic empyema with BPF.

**Closed irrigation**

Pleural space irrigation has been advocated as an alternative
method of treating empyema and space after pneumonectomy, especially with early infections. Irrigation may also be useful in sterilizing a chronic empyema in patients who would not readily tolerate an extensive and aggressive procedure (35,36).

To reduce morbidity and length of hospital stay of patients with early postpneumonectomy empyema, Gharagozloo and colleagues explored the technique of pleural space irrigation as a further modification of the “Clagett” procedure (37). All patients were treated with debridement thoracotomy and one-time surgical treatment of BPF. Then, the pleural space was irrigated with 0.1% povidone-iodine solution (Betadine; 40 mL/h) through 2 catheters placed in the 2nd intercostal space and evacuated with 2 chest tubes for 7 days. On day 8, the povidone-iodine irrigation was discontinued, and the pleural space was irrigated with normal saline solution (40 mL/h) for 24 hours. On day 9, the chest tube drainage fluid was stained to assess the status of the infection. If cultures were negative, the pleural space was filled with 2 L of DAB solution (gentamicin 80 mg/L, neomycin 500 mg/L, and polymyxin B 100 mg/L), and the irrigation and drainage catheters were removed. This technique requires a single surgical procedure and results in significantly shorter hospitalization and decreased morbidity in a selected subset of patients with postpneumonectomy empyema.

The combination of optimal management of the postpneumonectomy bronchial stump, either to treat or avoid BPF, and complete debridement of the pleural cavity and pleural irrigation may be comparable with open drainage with packing of the contaminated space. The main goals are to keep the infection under control and to sterilize the cavity. Inasmuch as there was no recurrence of BPF or empyema in Gharagozloo's series (37), pleural space irrigation followed by obliteration of the pleural space with an antibiotic solution represents a good option for patients with early post-pneumonectomy empyema and no BPF or a small BPF.

Video-assisted thoracoscopic surgery (VATS)

Nowadays, a minimally invasive approach is being increasingly adopted in the therapeutic arsenal to treat postpneumonectomy empyema (Figure 3). Local control of the infection through debris removal and cavity lavage is performed minimally invasively by avoiding an open thoracotomy or even thoracoplasty. In 3 publications reporting the use of video-assisted thoracoscopic surgery (VATS) for the management of empyema after pneumonectomy, the thoracoscopic procedure was combined with the pleural irrigation technique. In all 3 series, there were no treatment failures during a 21-month follow-up (38-40). More recently, a publication by Gossot and colleagues reported a series of 11 cases of empyema in postpneumonectomy patients (41). In this series, pleural irrigation was not used as part of their strategy, the patients had immediate chest tube drainage and underwent emergency thoracoscopic debridement of the empyema. In 3 cases, reoperation was necessary due to the maintenance of infectious signs and the patients underwent open drainage thoracostomy. The successful rate of this series was 73%.

All 4 series proved that the VATS approach is useful for selected patients with early postpneumonectomy empyema including those with small BPFs, although with a very limited number of patients. However, the method seems difficult to apply in patients with late postpneumonectomy empyema and is contraindicated for patients with large BPFs. The main advantages of thoracoscopic approach are the high cure rate and the dramatically reduction in chest drainage duration and hospital stay. VATS treatment does not preclude more aggressive surgical management in cases of failure or relapse.
Bronchopleural fistula management

Endoscopic approach

Endoscopic treatment of BPF can be performed either by flexible or rigid bronchoscopy and with either sedation or general anesthesia. The approach is physician dependent. Different materials have been used to close fistulas; however, the principle is the same: to achieve immediate mechanical closure by directly application of the substance followed by scar tissue formation.

In the short-term, primary endoscopic closure of BPFs has the potential benefits of decreasing air leak and pleural contamination and preventing contralateral aspiration of the pleural fluid. In long-term, it is also possible to achieve definitive BPF closure with an endoscopic approach. Success rate is related to the fistula size (42-44). In a retrospective series of 35 patients who underwent bronchoscopy repair of BPFs after pneumonectomy, Cardillo and colleagues demonstrated a successful repair in 92.3% of patients with BPF ≤2 mm in size, 71.4% for BPF >2 and ≤3 mm, 80% for BPF >3 and ≤6 mm, and only 33.3% in patients with BPF >6 mm (43). In patients with BPF with mucosal necrosis, the failure rates are high, and therefore, surgical treatment is advisable in these patients (43).

Biological glues

Different types of biological glues have been used to close BPFs including fibrin-based glues, cyanoacrylate-based glues (e.g., Histoacryl®), and albumin-glutaraldehyde tissue adhesive (BioGlue®) (45,46). The glue is directly applied in the fistula through a thin-catheter introduced in the working channel of a flexible bronchoscope. A plug promotes mechanical closure of the fistula, and an instantaneous cessation of air leak is expected (43). The glue may also be injected in the submucosa with a 21G needle in order to decrease plug displacement (45). Regardless of the substance and technique used, posterior inflammatory tissue growth helps achieving long-term BPF closure (48). This technique seems to work best for very small fistulae (up to 3 mm) (45).

Sclerosing agents

Sclerosing agents are also used to manage BPFs and may be applied directly to the mucosa of the fistula or injected in the submucosa. Initially, a local edema might occlude the trajectory; however, the subsequent inflammatory reaction and scar tissue formation are the main mechanisms for definitive BPF closure (49,50). Repeated applications are frequently needed. Stratakos and colleagues reported an 81.8% success rate in a series of 11 patients with postpneumonectomy or postlobectomy BPF ≤5 mm treated with mucosal application of melted silver nitrate applied through a flexible bronchoscope and using a cytology brush (51). Varoli and coworkers successfully treated 23 out of 35 patients (65%) with partial postpneumonectomy or postlobectomy bronchial stump dehiscence (up to 10 mm) by sequential injections of 4–5 mL of 2% polidocanol in the fistula submucosa, achieving complete healing after a mean of 5.5 weeks (52).

Occluding devices

Some occluder devices originally used for transcatheter closure of cardiac septal defects or patent ductus arteriosum closure, such as Amplatzer septal occluder (ASO), Amplatzer ductal occluder (ADO) and Amplatzer vascular plug (AVP) (AGA Medical, Golden Valley, Minn., USA), have been reported as options for BPF closure (53-56). ASO and ADO are double-disk occluders with a waist between them better suited for large fistulae with long communicating tract (>10 mm) before the pleural cavity (55). AVP is a self-expandable cylindrical device used for vessel occlusion mostly applied for small short-necked and pin-shaped BPFs (56). All three devices are deployed under direct bronchoscopic and fluoroscopic vision (55). Experience with these techniques for BPF treatment is limited but with promising results. Fruchter and colleagues published a series of 31 patients with postpneumonectomy and postlobectomy BPF treated with occluding devices. Immediate BPF closure was observed in 30 out of 31 patients (96%). After 6 months, 22 patients were alive, and all the devices were covered by granulation tissue (57).

Recently, Han and colleagues reported their experience with an endoscopic treatment of 148 patients with BPF post-pulmonary resection in which they used customized self-expandable covered metallic stents to occlude the fistula (58). Stent customization was performed based on measurements acquired by chest CT, bronchoscopy and bronchography with water-soluble contrast. Stent shape (Y-shaped, L-shaped or hinged) was based on the fistula location and bronchial stump length. The stent was correctly placed in the first attempt in 96.6% of the patients, resulting in complete occlusion of the fistula and short-term relief of clinical manifestations in 141
patients. Seventy-three patients were considered cured with complete obliteration of the pleural cavity and had their stent removed after a mean of 110 days. The success rate was higher for post-lobectomy fistulae (85%) than post-pneumonectomy fistulae (38%). The major complication rate was low, however, proliferation of granulation tissue at the extremity of the stent was a problem, which led to respiratory symptoms due to airway obstruction and ultimately to stent removal in 51 patients.

**Transpleural approach**

After the infection in the pleural cavity is under control, surgical closure of BPFs is commonly attempted through conventional thoracotomy or open window thoracotomy. The first step is to identify the fistula’s size and location and evaluate the presence of necrosis. Then, debridement of devitalized tissue is performed. Dissection of the bronchial stump can be challenging depending on the level of local fibrosis and proximity to important structures, commonly the pulmonary artery. When bronchial stump dissection is feasible and safe, the fistula may be directly closed with absorbable or non-absorbable sutures or even stapled in cases of long stumps, which are more common in acute BPF (59). After a standard closure, reinforcement of the closed BPF should be done with muscle flap or other vascularized tissue, such as omentum (60-62). In circumstances where the bronchial stump is not amenable to dissection, BPF closure may be accomplished by creating a “plug” with a muscle flap. A series from the Mayo Clinic reported the outcomes of 55 patients with BPF closure using muscle flaps and demonstrated a success rate of 82%. Bronchial stump closure and reinforcement with a serratus anterior muscle flap was the most used technique.

**Transsternal transpericardial approach**

In situations where the access to the bronchial stump is not feasible through the conventional transpleural approach, a transsternal transpericardial approach might be undertaken (59). This approach can be useful in patients with a prior attempt of BPF closure by thoracotomy or with a very short stump, mainly seen after a BPF caused by a left pneumonectomy. After a standard median sternotomy, the anterior pericardium is opened, and the superior vena cava and aorta are retracted laterally. The right pulmonary artery is retracted inferiorly. A window is made in the posterior pericardium, and good exposure of the carina and main bronchi is obtained to allow safe manipulation of the bronchial stump (63). In a retrospective series of 55 patients, De la Riviere and colleagues reported recurrence of BPF in 23.6% of patients using this approach (64). Whereas, Topcuoglu and coworkers described a success rate of 100% with no recurrence in 15 patients (65).

**Conclusions**

After pneumonectomy, patients who develop the complications of BPF and empyema exhibit high morbidity and mortality rates. The management of the BPF is a challenge. Accurate and expedited diagnosis is critical to achieve a cure. Regardless of the technique adopted for treatment, adequate pleural drainage, definitive closure of the BPF, sterilization of the pleural cavity, and obliteration of residual space are the key factors to favorable outcomes. Less invasive techniques, when clearly indicated and in selected patients, seem to be a good strategy and do not preclude the possibility of a more aggressive approach, if warranted.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/shc.2020.03.11). The authors have no conflicts of interest to declare.

**Ethical Statement:** The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References

54. Han X, Yin M, Li L, et al. Customized airway stenting for bronchopleural fistula after pulmonary resection by interventional technique: single-center study of 148

doi: 10.21037/shc.2020.03.11
Cite this article as: Azevedo I, Oliveira RL, Ugalde PA. Management of postpneumonectomy empyema and bronchopleural fistula. Shanghai Chest 2020.